Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Nov;70(11):7948–7957. doi: 10.1128/jvi.70.11.7948-7957.1996

Progress toward the development of a genetically engineered attenuated hepatitis A virus vaccine.

A W Funkhouser 1, G Raychaudhuri 1, R H Purcell 1, S Govindarajan 1, R Elkins 1, S U Emerson 1
PMCID: PMC190867  PMID: 8892918

Abstract

Mutations which positively affect growth of hepatitis A virus in cell culture may negatively affect growth in vivo. Therefore, development of an attenuated vaccine for hepatitis A may require a careful balancing of mutations to produce a virus that will grow efficiently in cells suitable for vaccine production and still maintain a satisfactory level of attenuation in vivo. Since such a balance could be achieved most directly by genetic engineering, we are analyzing mutations that accumulated during serial passage of the HM-175 strain of hepatitis A virus in MRC-5 cell cultures in order to determine the relative importance of the mutations for growth in MRC-5 cells and for attenuation in susceptible primates. Chimeric viral genomes of the HM-175 strain were constructed from cDNA clones derived from a virulent virus and from two attenuated viruses adapted to growth in African green monkey kidney (AGMK) and MRC-5 cells, respectively. Viruses encoded by these chimeric genomes were recovered by in vitro or in vivo transfection and assessed for their ability to grow in cultured MRC-5 cells or to cause hepatitis in primates (tamarins). The only MRC-5-specific mutations that substantially increased the efficiency of growth in MRC-5 cells were a group of four mutations in the 5' noncoding (NC) region. These 5' NC mutations and a separate group of 5' NC mutations that accumulated during earlier passages of the HM-175 virus in primary AGMK cells appeared, independently and additively, to result in decreased biochemical evidence of hepatitis in tamarins. However, neither group of 5' NC mutations had a demonstrable effect on the extent of virus excretion or liver pathology in these animals.

Full Text

The Full Text of this article is available as a PDF (331.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. André F. E., Hepburn A., D'Hondt E. Inactivated candidate vaccines for hepatitis A. Prog Med Virol. 1990;37:72–95. [PubMed] [Google Scholar]
  2. Brown E. A., Day S. P., Jansen R. W., Lemon S. M. The 5' nontranslated region of hepatitis A virus RNA: secondary structure and elements required for translation in vitro. J Virol. 1991 Nov;65(11):5828–5838. doi: 10.1128/jvi.65.11.5828-5838.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown E. A., Zajac A. J., Lemon S. M. In vitro characterization of an internal ribosomal entry site (IRES) present within the 5' nontranslated region of hepatitis A virus RNA: comparison with the IRES of encephalomyocarditis virus. J Virol. 1994 Feb;68(2):1066–1074. doi: 10.1128/jvi.68.2.1066-1074.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen J. I., Rosenblum B., Feinstone S. M., Ticehurst J., Purcell R. H. Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA. J Virol. 1989 Dec;63(12):5364–5370. doi: 10.1128/jvi.63.12.5364-5370.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen J. I., Rosenblum B., Ticehurst J. R., Daemer R. J., Feinstone S. M., Purcell R. H. Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2497–2501. doi: 10.1073/pnas.84.8.2497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cohen J. I., Ticehurst J. R., Feinstone S. M., Rosenblum B., Purcell R. H. Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J Virol. 1987 Oct;61(10):3035–3039. doi: 10.1128/jvi.61.10.3035-3039.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cohen J. I., Ticehurst J. R., Purcell R. H., Buckler-White A., Baroudy B. M. Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J Virol. 1987 Jan;61(1):50–59. doi: 10.1128/jvi.61.1.50-59.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cui T., Porter A. G. Localization of binding site for encephalomyocarditis virus RNA polymerase in the 3'-noncoding region of the viral RNA. Nucleic Acids Res. 1995 Feb 11;23(3):377–382. doi: 10.1093/nar/23.3.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Daemer R. J., Feinstone S. M., Gust I. D., Purcell R. H. Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage. Infect Immun. 1981 Apr;32(1):388–393. doi: 10.1128/iai.32.1.388-393.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Day S. P., Murphy P., Brown E. A., Lemon S. M. Mutations within the 5' nontranslated region of hepatitis A virus RNA which enhance replication in BS-C-1 cells. J Virol. 1992 Nov;66(11):6533–6540. doi: 10.1128/jvi.66.11.6533-6540.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dienstag J. L., Popper H., Purcell R. H. The pathology of viral hepatitis types A and B in chimpanzees. A comparison. Am J Pathol. 1976 Oct;85(1):131–148. [PMC free article] [PubMed] [Google Scholar]
  12. Emerson S. U., Huang Y. K., Purcell R. H. 2B and 2C mutations are essential but mutations throughout the genome of HAV contribute to adaptation to cell culture. Virology. 1993 Jun;194(2):475–480. doi: 10.1006/viro.1993.1286. [DOI] [PubMed] [Google Scholar]
  13. Emerson S. U., Lewis M., Govindarajan S., Shapiro M., Moskal T., Purcell R. H. cDNA clone of hepatitis A virus encoding a virulent virus: induction of viral hepatitis by direct nucleic acid transfection of marmosets. J Virol. 1992 Nov;66(11):6649–6654. doi: 10.1128/jvi.66.11.6649-6654.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Emerson S. U., McRill C., Rosenblum B., Feinstone S., Purcell R. H. Mutations responsible for adaptation of hepatitis A virus to efficient growth in cell culture. J Virol. 1991 Sep;65(9):4882–4886. doi: 10.1128/jvi.65.9.4882-4886.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Funkhouser A. W., Purcell R. H., D'Hondt E., Emerson S. U. Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells. J Virol. 1994 Jan;68(1):148–157. doi: 10.1128/jvi.68.1.148-157.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Glass M. J., Summers D. F. A cis-acting element within the hepatitis A virus 5'-non-coding region required for in vitro translation. Virus Res. 1992 Oct;26(1):15–31. doi: 10.1016/0168-1702(92)90143-w. [DOI] [PubMed] [Google Scholar]
  17. Haller A. A., Nguyen J. H., Semler B. L. Minimum internal ribosome entry site required for poliovirus infectivity. J Virol. 1993 Dec;67(12):7461–7471. doi: 10.1128/jvi.67.12.7461-7471.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Haller A. A., Stewart S. R., Semler B. L. Attenuation stem-loop lesions in the 5' noncoding region of poliovirus RNA: neuronal cell-specific translation defects. J Virol. 1996 Mar;70(3):1467–1474. doi: 10.1128/jvi.70.3.1467-1474.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Harmon S. A., Richards O. C., Summers D. F., Ehrenfeld E. The 5'-terminal nucleotides of hepatitis A virus RNA, but not poliovirus RNA, are required for infectivity. J Virol. 1991 May;65(5):2757–2760. doi: 10.1128/jvi.65.5.2757-2760.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hellen C. U., Wimmer E. Translation of encephalomyocarditis virus RNA by internal ribosomal entry. Curr Top Microbiol Immunol. 1995;203:31–63. doi: 10.1007/978-3-642-79663-0_2. [DOI] [PubMed] [Google Scholar]
  21. Jansen R. W., Newbold J. E., Lemon S. M. Complete nucleotide sequence of a cell culture-adapted variant of hepatitis A virus: comparison with wild-type virus with restricted capacity for in vitro replication. Virology. 1988 Apr;163(2):299–307. doi: 10.1016/0042-6822(88)90270-x. [DOI] [PubMed] [Google Scholar]
  22. Karron R. A., Daemer R., Ticehurst J., D'Hondt E., Popper H., Mihalik K., Phillips J., Feinstone S., Purcell R. H. Studies of prototype live hepatitis A virus vaccines in primate models. J Infect Dis. 1988 Feb;157(2):338–345. doi: 10.1093/infdis/157.2.338. [DOI] [PubMed] [Google Scholar]
  23. Krawczynski K. K., Bradley D. W., Murphy B. L., Ebert J. W., Anderson T. E., Doto I. L., Nowoslawski A., Duermeyer W., Maynard J. E. Pathogenetic aspects of hepatitis A virus infection in enterally inoculated marmosets. Am J Clin Pathol. 1981 Nov;76(5):698–706. doi: 10.1093/ajcp/76.5.698. [DOI] [PubMed] [Google Scholar]
  24. Leong L. E., Walker P. A., Porter A. G. Human rhinovirus-14 protease 3C (3Cpro) binds specifically to the 5'-noncoding region of the viral RNA. Evidence that 3Cpro has different domains for the RNA binding and proteolytic activities. J Biol Chem. 1993 Dec 5;268(34):25735–25739. [PubMed] [Google Scholar]
  25. Midthun K., Ellerbeck E., Gershman K., Calandra G., Krah D., McCaughtry M., Nalin D., Provost P. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis. 1991 Apr;163(4):735–739. doi: 10.1093/infdis/163.4.735. [DOI] [PubMed] [Google Scholar]
  26. Nalin D. R., Kuter B. J., Brown L., Patterson C., Calandra G. B., Werzberger A., Shouval D., Ellerbeck E., Block S. L., Bishop R. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol. 1993;18 (Suppl 2):S51–S55. doi: 10.1016/s0168-8278(05)80379-4. [DOI] [PubMed] [Google Scholar]
  27. Provost P. J., Bishop R. P., Gerety R. J., Hilleman M. R., McAleer W. J., Scolnick E. M., Stevens C. E. New findings in live, attenuated hepatitis A vaccine development. J Med Virol. 1986 Oct;20(2):165–175. doi: 10.1002/jmv.1890200208. [DOI] [PubMed] [Google Scholar]
  28. Ran L. A., Wang D. Z., Duan Q. Y., Yan T. Y., Liu Q. L., Luo Y. G., Yang D. Z., Yang D. F., Xiao Z., Xie Q. J. Safety and immunogenicity of live attenuated hepatitis A virus vaccine (H2 strain) in humans. Chin Med J (Engl) 1993 Aug;106(8):604–607. [PubMed] [Google Scholar]
  29. Schultheiss T., Kusov Y. Y., Gauss-Müller V. Proteinase 3C of hepatitis A virus (HAV) cleaves the HAV polyprotein P2-P3 at all sites including VP1/2A and 2A/2B. Virology. 1994 Jan;198(1):275–281. doi: 10.1006/viro.1994.1030. [DOI] [PubMed] [Google Scholar]
  30. Schultz D. E., Honda M., Whetter L. E., McKnight K. L., Lemon S. M. Mutations within the 5' nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey kidney cells. J Virol. 1996 Feb;70(2):1041–1049. doi: 10.1128/jvi.70.2.1041-1049.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Shaffer D. R., Brown E. A., Lemon S. M. Large deletion mutations involving the first pyrimidine-rich tract of the 5' nontranslated RNA of human hepatitis A virus define two adjacent domains associated with distinct replication phenotypes. J Virol. 1994 Sep;68(9):5568–5578. doi: 10.1128/jvi.68.9.5568-5578.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Shapiro C. N., Coleman P. J., McQuillan G. M., Alter M. J., Margolis H. S. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine. 1992;10 (Suppl 1):S59–S62. doi: 10.1016/0264-410x(92)90545-u. [DOI] [PubMed] [Google Scholar]
  33. Sjogren M. H., Purcell R. H., McKee K., Binn L., Macarthy P., Ticehurst J., Feinstone S., Caudill J., See A., Hoke C. Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate. Vaccine. 1992;10 (Suppl 1):S135–S137. doi: 10.1016/0264-410x(92)90568-5. [DOI] [PubMed] [Google Scholar]
  34. Vallbracht A., Maier K., Stierhof Y. D., Wiedmann K. H., Flehmig B., Fleischer B. Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis. 1989 Aug;160(2):209–217. doi: 10.1093/infdis/160.2.209. [DOI] [PubMed] [Google Scholar]
  35. Van Damme P., Thoelen S., Cramm M., De Groote K., Safary A., Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994 Dec;44(4):446–451. doi: 10.1002/jmv.1890440425. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES